Editas Q1 2023 Earnings Report
Key Takeaways
Editas Medicine reported its Q1 2023 financial results, featuring a net loss of $49.0 million, or $0.71 per share. Collaboration and other research and development revenues increased, while research and development expenses remained relatively flat. The company is progressing with its EDIT-301 program and anticipates several clinical updates throughout the year.
Editas is on track to dose 20 total patients by year-end in the RUBY trial for SCD.
The first patient in EDIT-301 EDITHAL trial for TDT was dosed with successful neutrophil and platelet engraftment.
Collaboration and other research and development revenues increased by $3.1 million to $9.9 million.
Editas Medicine will present a clinical update from the RUBY trial in June at EHA.
Editas
Editas
Forward Guidance
Editas Medicine anticipates several clinical updates and remains focused on advancing its EDIT-301 program.
Positive Outlook
- On track to dose 20 total patients by year-end in the RUBY trial.
- First patient in EDIT-301 EDITHAL trial for TDT dosed with successful neutrophil and platelet engraftment.
- Company on track to provide clinical update from the EDITHAL trial by year-end.
- Editas Medicine will present a clinical update from the RUBY trial in June.
- Existing cash, cash equivalents and marketable securities to fund operating expenses and capital expenditures into 2025.